Randomized placebo controlled trial of lofexidine hydrochloride for chronic pelvic pain in women
Randomized placebo controlled trial of lofexidine hydrochloride for chronic pelvic pain in women
Background: We hypothesised that the orally-active 2-adrenoceptor agonist lofexidine hydrochloride would ameliorate chronic pelvic pain in women.
Methods: A randomized placebo-controlled parallel group trial was undertaken in the University Hospital Gynaecology Clinic. Women with pelvic pain of at least 6 months duration were eligible, and were randomized using a sealed envelope system to receive up to 600 mg lofexidine hydrochloride twice daily over 8 weeks or placebo. Outcome measures were summary and daily diary visual analog scales for pain (VAS) and a 5 point self rating scale.
Results: 9/19 women randomized to lofexidine completed the study compared to 14/20 of those randomized to placebo. Intention-to-treat analysis showed that 4/19 in the lofexidine group achieved 50% or greater reduction in VAS compared with 8/20 in the placebo group (OR 2.5, 95% CI 0.6–10.3). Summary and diary VAS were closely correlated.
Conclusions: Within the limits of a small study with power to detect only a substantial effect, we conclude that lofexidine hydrochloride is not effective for the treatment of chronic pelvic pain.
chronic pelvic pain, lofexidine hydrochloride, women
1719-1721
Stones, R. William
cc80809c-04a3-4dc0-8771-820de97c312d
Bradbury, Lucy
b5cdf78e-a486-43c4-a46f-68d329fcb677
Anderson, Denise
7af6b389-1e50-4e5c-9497-679e8e55eb37
2001
Stones, R. William
cc80809c-04a3-4dc0-8771-820de97c312d
Bradbury, Lucy
b5cdf78e-a486-43c4-a46f-68d329fcb677
Anderson, Denise
7af6b389-1e50-4e5c-9497-679e8e55eb37
Stones, R. William, Bradbury, Lucy and Anderson, Denise
(2001)
Randomized placebo controlled trial of lofexidine hydrochloride for chronic pelvic pain in women.
Human Reproduction, 16 (8), .
Abstract
Background: We hypothesised that the orally-active 2-adrenoceptor agonist lofexidine hydrochloride would ameliorate chronic pelvic pain in women.
Methods: A randomized placebo-controlled parallel group trial was undertaken in the University Hospital Gynaecology Clinic. Women with pelvic pain of at least 6 months duration were eligible, and were randomized using a sealed envelope system to receive up to 600 mg lofexidine hydrochloride twice daily over 8 weeks or placebo. Outcome measures were summary and daily diary visual analog scales for pain (VAS) and a 5 point self rating scale.
Results: 9/19 women randomized to lofexidine completed the study compared to 14/20 of those randomized to placebo. Intention-to-treat analysis showed that 4/19 in the lofexidine group achieved 50% or greater reduction in VAS compared with 8/20 in the placebo group (OR 2.5, 95% CI 0.6–10.3). Summary and diary VAS were closely correlated.
Conclusions: Within the limits of a small study with power to detect only a substantial effect, we conclude that lofexidine hydrochloride is not effective for the treatment of chronic pelvic pain.
This record has no associated files available for download.
More information
Published date: 2001
Keywords:
chronic pelvic pain, lofexidine hydrochloride, women
Identifiers
Local EPrints ID: 37808
URI: http://eprints.soton.ac.uk/id/eprint/37808
PURE UUID: 9650c081-2b17-4225-8979-0be4a0d8e8ac
Catalogue record
Date deposited: 01 Jun 2006
Last modified: 08 Jan 2022 12:57
Export record
Contributors
Author:
R. William Stones
Author:
Lucy Bradbury
Author:
Denise Anderson
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics